Researchers Give People Lab-Grown Blood in World’s First Clinical Trial

Lab-grown blood could fill this gap—and researchers are already testing the stuff in human study participants. The project, called RESTORE, is a collaboration between scientists from three universities in the United Kingdom, as well as from England’s National Health System Blood and Transplant (NHSBT). The goal is to supplement the natural blood supply with fabricated red blood cells, which are grown from human stem cells.

To make the blood, RESTORE scientists obtain a standard pint-sized blood donation from a human donor. They then use magnetic beads to separate about 500,000 stem cells out from the rest of the tissue. Over the span of three weeks, these stem cells are encouraged to multiply until they reach a population of about 50 billion, approximately 15 billion of which are considered to be at the appropriate stage of development for transplant. Because these cells are at this specific stage, researchers actually expect recipients’ bodies to accept the lab-grown blood at a higher rate than they would a standard blood transfusion.

Their theory seems to track so far—though the team still has a long way to go. RESTORE researchers have officially transfused the lab-grown blood into two healthy recipients, each of whom received five to 10 milliliters (approximately one to two teaspoons). Though RESTORE hasn’t shared when exactly the transfusions took place, both recipients are said to be “well and healthy” with “no untoward side effects” having been reported so far. At least eight more clinical trial participants will receive lab-grown blood transfusions at least four months after receiving a standard blood transfusion, which will allow the RESTORE team to compare physical reactions to each. Mild radioactive “tagging” of the lab-grown blood cells allows researchers to monitor which reactions are a result of the experimental transfusion.

“We hope our lab-grown red blood cells will last longer than those that come from blood donors,” said the study’s chief investigator Professor Cedric Ghevaert, consultant hematologist at the University of Cambridge and NHSBT, in a statement. “If our trial, the first such in the world, is successful, it will mean that patients who currently require regular long-term blood transfusions will need fewer transfusions in the future, helping transform their care.”

Though lab-grown blood cells are bound to be useful in specific contexts—such as situations requiring rare blood types—experts warn they won’t replace standard blood donations. Creating blood in a lab is expensive and time-consuming, while a standard donation costs the NHS approximately £130 and can be used relatively quickly.

“We should remember that the NHS still needs 250 blood donations every day…and the figure is rising,” said John James, chief executive of the Sickle Cell Society. “The need for normal blood donations to provide the vast majority of blood transfusions will remain.”

Continue reading

Elon Musk: SpaceX Will Send People to Mars in 4 to 6 Years

SpaceX and Tesla CEO Elon Musk likes to make bold claims. Sometimes he comes through, and we end up with a reusable Falcon 9 rocket, but Musk also has a tendency to get carried away, particularly when it comes to Mars. The SpaceX CEO has long promised a Mars colony on an aggressive, and some…

190,000 Ceiling Fans Recalled After Blades Fly Off, Hitting People

King of Fans is recalling some 190,000 ceiling fans sold through Home Depot after the blades began detaching during operation.

Signia Active Hearing Aids Review: For People Who Love Earbuds

For many people, the idea of wearing hearing aids comes with a stigma, even if it would benefit them. So hearing aid companies have been working on new form factors to try and make that less of an issue. We review one of the latest, the earbud-shaped Active Pro model from Signia.

Newegg Forced People to Buy Gigabyte Power Supplies With Catastrophic Failure Rates

An investigation into Gigabyte power supplies has found that an unacceptable number of units suffer failures, many of them explosively. What makes all of this worse is that the same two model numbers known to be affected were part of Newegg's forced bundling program earlier this year.